Abstract. RC-RNase exerts anti-cancer effects on many tumors. However, the mechanisms by which RC-RNase induces cytotoxicity in different tumor cells are unclear. Currently, estrogen receptor (ER)-positive and negative breast tumors are treated with RC-RNase. Our data demonstrate that RC-RNase induces cell death on ER-positive but not on ERnegative breast tumors. This study also shows that downregulation of ER and Bcl-2 is found on RC-RNase-treated ER-positive breast tumors. Additionally, Bcl-2 ovexpression can prevent ER-positive breast tumors from cell death treated with RC-RNase. In summary, this study demonstrates that RC-RNase-induced cell death of ER-positive breast tumors is through regulation of ER and Bcl-2.
tumors but cytotoxicity was not inducted on MDA-MB-231 and ZR-75-30 containing tumors. This result indicated that RC-RNase can induce different cytotoxicity on breast tumors depending on its receptors. Therefore, MCF-7, MDA-MB-231, ZR-75-1 and ZR-75-30 containing breast tumors are widely used to study the target sites of RC-RNase activity on breast tumors.
Many reports have shown that ER-positive breast tumors have MCF-7 and ZR-75-1 (16) (17) (18) (19) while ER-negative tumors have MDA-MB-231 and ZR-75-30 (20) (21) (22) . Primarily, data presented in this report show that RC-RNase induces cell death on MCF-7 and ZR-75-1 tumors, but not on MDA-MB-231 and ZR-75-30 tumors. That is, RC-RNase only induces cell death on ER-positive breast tumors. We further study estrogen receptor level on RC-RNase-treated ER-positive breast tumors. Our data showed that RC-RNase can induce down-regulation of ER. Therefore, ER is an important target of RC-RNase-induced cytotoxicity on ER-positive breast tumors. In addition, our data showed that down-regulation of Bcl-2 was found on RC-RNase-treated ER-positive breast tumors. Previous studies indicated that Bcl-2 and Bcl-XL belong to Bcl-2 family and demonstrated that overexpression of Bcl-2 or Bcl-XL has anti-apoptosis effects (23) (24) (25) (26) . However, our previous study demonstrated that overexpression of Bcl-XL can not inhibit RC-RNase-induced cytotoxicity on ER-positive breast tumors (5). We investigated whether Bcl-2 can inhibit RC-RNase-induced cytotoxicity. Our study showed that overexpression of Bcl-2 can inhibit RC-RNase-inudced cytotoxicity on ER-positive breast tumors. Overall, we firstly demonstrated that RC-RNase induces cytotoxicity on ER-positive breast tumors, but not on ER-negative breast tumors through ER and Bcl-2 downregulation.
Materials and methods
Reagents and cell culture. RC-RNase was purified with the modified methods described in previous studies (5, 6, 11) . Ac-DEVD-pNA (Acetyl-Asp-Glu-Val-Asp-p-nitroanilide) was purchased from Anaspec (San Jose, CA). XTT assay kit was procured from Roche (Mannheim, Germany). Bcl-2 antibody was purchased from Upstate. ER and actin antibodies were commissioned from Pharmingen Laboratories (San Diego, CA), and Chemicon Laboratories (Temecula, CA), respectively. Dr Jiang (Tzu Chi General Hospital) provided the human breast carcinoma cells with MCF-7, MDA-MB-231, ZR-75-1 and ZR-75-30 and cultures were made using Dulbecco's Modified Eagle Medium (Gibco BRL) supplemented with 10%-heat-inactivated-fetal-bovine serum (Hyclone ® Laboratories, Inc., Logan, UT), 2 mM L-glutamine (Gibco BRL), 100 IU/ml penicillin G sodium (Gibco BRL), 100 μg/ml streptomycin sulfate (Gibco BRL), 1 mM sodium pyruvate (Sigma Chemical Co., St. Louis, MO) and 0.1 mM non-essential amino acids (Gibco BRL).
Survival rate assay. Cell survival rate was determined using XTT {sodium 3'-[1-(phenylamino-carbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate} kit which analyzes the activity of mitochondrial dehydrogenase. Briefly, 2x10
3 -cells were grown in each well of 96-wellcontaining cell culture plates overnight. The following day, these cells were treated with RC-RNase. XTT assays were carefully performed every 24 h following instructions from the manufacturer. Absorbance was determined at 492 nm using a multi-well ELISA reader (Molecular Devices, Sunnyvale, CA).
Caspase activity assay. Cells were treated with the lytic buffer (50 mM Tris-HCl, 120 mM NaCl, 1 mM EDTA, 1% NP-40, pH 7.5) supplemented with protease inhibitors. Cell pellets were removed via centrifugation at 15000 x g for 20 min at 4˚C. The caspase activity assay was determined in a reaction solution containing 40 μl cell lysates (80 μg total protein), 158 μl of reaction buffer (20% glycerol, 0.5 mM EDTA, 5 mM dithiothreitol, 100 mM HEPES, pH 7.5) and 2 μl of fluorogenic Ac-DEVD-pNA and was incubated at 37˚C for 6 h. The fluorogenic substrate cleavage readout was the pnitroanilide release as detected at 405 nm in an ultra-microplate reader (Bio-Tek instruments).
Western blot analysis. Cells were collected using cell scrapers and lysed in RIPA buffer (10 mM Tris-base, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitors (Calbiochem, La Jolla, CA). Equal amounts of the total proteins were loaded into a 13.3% SDS-polyacrylamide gel and underwent electrophoresis. They were then transferred to a polyvinyldene difluoride membrane (Amersham Pharmacia Biotech). The membranes were blocked with 5% skim milk and 1% NP-40 in TBS-T (0.8% NaCl, 0.02% KCl, 25 mM Tris-HCl, 0.05% Tween-20, at pH 7.4) for 1 h, incubated with the primary antibody (1:500 dilution in the blocking buffer) at 4˚C overnight, and subsequent incubation was done with biotinylated anti-mouse or anti-rabbit IgG (1:1000 or 1:10000 dilution in the blocking buffer) and streptavidin-horseradish peroxidase conjugates (1:2000 dilution in PBS). The membranes were developed using the Super Signal™ chemiluminescent-HRP substrate system (Pierce, Rockford, IL).
Establishment of transfectants overexpressing Bcl-2 and
Bcl-XL. Human Bcl-2/PCR 3.1 and Bcl-XL/PCR 3.1 plasmids were constructed employing methods as mentioned previously (5) . MCF-7 cells were transfected with Bcl-2/PCR 3.1 or Bcl-XL/PCR 3.1 plasmids using lipofectamine (Gibco) and selected by 400 μg/ml geneticin (Gibco). These transfectants were cultured in the 96-well plates to make a single cell per well. After a single cell became confluent, they were transferred to 25-T flasks and cultured with complete medium using 400 μg/ml geneticin. Transfectants overexpressing Bcl-2 and Bcl-XL were determined using the Western blot method. To demonstrate this idea, ER was determined by Western blotting. Our result showed that degradation of ER can be found on RC-RNase-treated ER-positive breast tumor cells in a dose-dependent manner (Fig. 2) . Additionally, degradation of Bcl-2 was found on RC-RNase-treated ERpositive breast tumor cells (Fig. 2) . Based on the observations and results in this study, it is highly suggestive that RC-ONCOLOGY REPORTS 00: 0-00, 0000 RNase induces cytotoxicity on ER-positive breast tumor cells through down-regulation of ER and Bcl-2.
Results

RC-RNase induces cytotoxicity and caspase-3-like activity on MCF-7 and ZR-
Overexpression of Bcl-2 inhibits RC-RNase-induced cytotoxicity on ER-positive breast tumors.
Transfectants overexpressing Bcl-2 and Bcl-XL was selected successfully in this study. As shown in Fig. 3A , MCF-7/Bcl-2 transfectants can express Bcl-2 and MCF-7/Bcl-XL transfectants can express Bcl-XL. MCF-7 cells and MCF-7/PCR 3.1 transfectants were used as a negative control. The survival rates of MCF-7, MCF-7/Bcl-2, MCF-7/Bcl-XL and MCF-7/PCR 3.1 with RC-RNase treatment showed that only MCF-7/Bcl-2 transfectants inhibited RC-RNase-induced cytotoxicity (Fig. 3B) while MCF-7/Bcl-XL transfectants did not (Fig.  3B) . We can deduce from our study that only Bcl-2 can inhibit RC-RNase-induced cytotoxicity on MCF-7 cells despite Bcl-2 and Bcl-XL both belonging to the antiapoptosis protein family.
Overexpression of Bcl-2 inhibits down-regulation of Bcl-2.
We further determined the expression of ER and Bcl-2 on RC-RNase-treated MCF-7/Bcl-2 transfectants. The result is shown in Fig. 4 . Comparing with Fig. 2 , down-regulation of Bcl-2 is clearer on RC-RNase-treated MCF-7 cells than RCRNase-treated MCF-7/Bcl-2 transfectants. Furthermore, our data indicate that down-regulation of ER was observed clearly on RC-RNase-treated MCF-7/Bcl-2 transfectants at day 3. This result is similar to that of ER down-regulation on RC-RNase-treated MCF-7 cells (Fig. 2) .
Discussion
Data from previous literature demonstrated that RC-RNase can induce cytotoxicity on breast tumors (MCF-7 cells) through caspase-7 activation (5,11). However, the target sites where RC-RNase will induce cytotoxicity on breast tumors are still unclear. In this study, our data showed that RCRNase induces cytotoxicity on ER-positive breast tumors (MCF-7 and ZR-75-1) but fails to induce cytotoxicity on ERnegative breast tumors (MDA-MB-231 and ZR-75-30). In other words, RC-RNase has an anti-cancer effect only on ER-positive breast tumors. Additionally, our study demonstrates that RC-RNase can induce down-regulation of ER on ER-positive breast tumors. ER-positive breast tumor treatments have demonstrated that cell proliferation can be inhibited on ER-positive breast tumors by blocking the ER signal pathway (27) (28) (29) (30) . Based on these studies and our results, we suggest that ER is an important target of RCRNase-induced cytotoxity on ER-positive breast tumors. Bcl-2 with anti-apoptotic functions and survival effects have also been demonstrated in some studies (31) (32) (33) . These studies indicated that various cell types cannot survive when Bcl-2 level decreased. Our study shows that down-regulation of Bcl-2 is expressed on ER-positive breast tumors treated with RC-RNase. Many studies have demonstrated that downregulation of Bcl-2 can induce cell death on ER-positive breast tumors (34) (35) (36) . These results are similar to our study. We therefore consider that Bcl-2 is also a target site of action for RC-RNase to induce cytotoxity on ER-positive breast tumors. Our study demonstrates that RC-RNase can downregulate ER and Bcl-2 levels resulting in cell death on ERpositive breast tumors.
Various reports have indicated that Bcl-2 and Bcl-XL are anti-apoptotic factors (23) (24) (25) (26) . These reports suggested that overexpression of Bcl-2 and Bcl-XL can inhibit cell death and the down-regulation of Bcl-2 and Bcl-XL can induce cell death. However, previous studies demonstrated that Bcl-2 overexpression cannot prevent hyperoxia-induced cell death on epithelial cells (37) and Bcl-XL overexpression cannot inhibit apoptosis on hepatocytes (38) . Additionally, it has been reported that Bcl-2 and Bcl-XL inhibit cell death in a different manner (39) . These studies indicated that antiapoptotic effects between Bcl-2 and Bcl-XL on different cells vary depending on the target site of action and cellular function (37) (38) (39) (40) . In this study, our results demonstrate that Bcl-XL overexpression can not inhibit RC-RNase-induced cytotoxicity on MCF-7 cells. This result is similar with our previous study (5) . Furthermore, our study shows that Bcl-2 overexpression can inhibit RC-RNase-induced cytotoxicity on ER-positive breast tumors indicating that the antiapoptotic effect on RC-RNase-treated ER-positive breast tumors is dependent on Bcl-2 functions but not on Bcl-XL functions.
In summary, this study is able to demonstrate that RCRNase induces cell death on ER-positive breast tumors but not on ER-negative breast tumors through down-regulation of ER and Bcl-2. In addition, the anti-cancer effect on RCRNase-treated ER-positive breast tumors is related to Bcl-2 overexpression, but not to Bcl-XL overexpression.
